EMP-01
Small molecule
Evidence outlook
Social Anxiety Disorder: topline reported 2026-02-26
The sponsor reported topline results on 2026-02-26 (EMP-01 Phase 2a topline in social anxiety disorder (placebo-adjusted LSAS -11.85 at Day 43)). The announcement is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06693609 NCT06693609 · Social Anxiety Disorder Registry: NCT06693609 | 2 | Incidence and severity of treatment emergent adverse events, adverse events of special interest and serious adverse events. (Day 1 to EOS [Day 43]); Incidence of clinically significant abnormalities in physical examinations, vital signs, electrocardiogram parameters, and safety laboratory results. (Day 1 [post-dose] to Day 57); Columbia-Suicide Severity Rating Scale (C-SSRS) Score (Baseline to Day 57) 2025-12-10 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Social Anxiety Disorder: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| EMP-01: this drug | Phase 2 | Small molecule | Serotonergic system (MDMA-class entactogen) | not yet graded | No reviewed efficacy summary in this indication | |
| Fasedienol | Phase 3 | Small molecule | Nasal chemosensory receptors | Partial signal | NCT04754802: Subjective Units of Distress Scale (SUDS) Score (Visit 2 (Baseline; Day 0) to Visit 3 (Day 7 ± 2 days)): PH94B — Visit 2: 77.7 score on a scale (Standard Deviation 11.67); Visit 3: 62.3 score on a scale (Standard Deviation 19.4) | Placebo — Visit 2: 78.2 score on a scale (Standard Deviation 12.42); Visit 3: 61.3 score on a scale (Standard Deviation 19.56) missed |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent